Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3 bispecific killer engager
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
B7-H3 bispecific killer engager is a **preclinical class of NK-cell engaging biologic immunotherapies** rather than a single uniquely defined drug product. These agents are typically engineered as **bispecific antibody fragment-based proteins** that bind **B7-H3** on tumor cells and **CD16** on natural killer cells, thereby promoting immune synapse formation, NK-cell activation, antibody-dependent cellular cytotoxicity-like killing, and cytokine release against B7-H3 expressing malignancies. Reported examples include a **B7-H3/CD16 BiKE** derived from the anti-B7-H3 antibody omburtamab and related research-stage constructs evaluated mainly in solid tumors such as **non-small cell lung cancer**; however, the queried term does not identify one proprietary clinical-stage asset, approved medicine, or single manufacturer.
- Other names
- B7-H3 BiKEB-7-H3 BiKEB 7-H3 BiKEB7-H3/CD16 BiKE
02
Targets
FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)B7-H3CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on B7-H3 bispecific killer engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3 bispecific killer engager.